Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | GLA | P06280 | 7/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 6/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.44 |
| ▸ | CASP1 | P29466 | 6/20 | 0.44 |
| ▸ | CASP7 | P55210 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187949 | 0.89 | ALDH1A1 (0.61) | ALDH1A1GLAHSD17B10MAPK1HPGD | |
| SCHEMBL189896 | 0.87 | ALDH1A1 (0.46) | ALDH1A1GLAHSD17B10MAPK1HPGD | |
| SCHEMBL189818 | 0.84 | PIK3CA (0.60) | ALDH1A1HSD17B10MAPK1CYP1A2CASP1 | |
| SCHEMBL2632978 | 0.71 | PIK3CA (0.53) | ALDH1A1GLAHSD17B10MAPK1HPGD | |
| SCHEMBL14306585 | 0.68 | METAP2 (0.37) | ALDH1A1GLAHSD17B10MAPK1HPGD | |
| SCHEMBL188527 | 0.68 | WEE1 (0.44) | ALDH1A1GLAHSD17B10MAPK1HPGD | |
| SCHEMBL15580678 | 0.67 | ALDH1A1 (0.48) | ALDH1A1GLAHSD17B10MAPK1HPGD | |
| SCHEMBL15580682 | 0.67 | PIK3CA (0.50) | ALDH1A1GLAHSD17B10MAPK1HPGD | |
| SCHEMBL3693426 | 0.67 | ALDH1A1 (0.81) | ALDH1A1GLAHSD17B10MAPK1HPGD | |
| SCHEMBL14300937 | 0.67 | PIK3CA (0.50) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172371-A1 | Methods of Treating Cancer Using Pyridopyrimidinone Inhibitors of PI3K and mTOR in Combination with Autophagy Inhibitors | EXELIXIS, INC (US) | 2013-07-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172371-A1 | Methods of Treating Cancer Using Pyridopyrimidinone Inhibitors of PI3K and mTOR in Combination with Autophagy Inhibitors | MTOR, PIK3CA, PIK3CD | ALDH1A1 2766/4885GLA 3879/4885HSD17B10 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.